Product Code: GMDHC2017TDB
Summary
Huntingtin (Huntington Disease Protein or HTT) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Huntingtin - Pipeline Review, H2 2019, outlays comprehensive information on the Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Huntingtin (Huntington Disease Protein or HTT) - Huntingtin protein is an encoded by the huntingtin gene, also called the HTT or HD (Huntington disease) gene. Huntingtin up regulates the expression of brain derived neurotrophic factor (BDNF) at the transcription level. Huntingtin is primarily associated with vesicles and microtubules.
These indicate an important role in cytoskeletal anchoring or transport of mitochondria. The Htt protein is involved in vesicle trafficking as it interacts with HIP1 to mediate endocytosis. Huntingtin also plays an important role in the establishment in epithelial polarity through its interaction with RAB11A. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 10 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Genetic Disorders which include indications Huntington Disease, Alzheimer's Disease, Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) and Spinocerebellar Ataxia (SCA).
Furthermore, this report also reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Huntingtin (Huntington Disease Protein or HTT)
- The report reviews Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics and enlists all their major and minor projects
- The report assesses Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Huntingtin (Huntington Disease Protein or HTT) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Huntingtin (Huntington Disease Protein or HTT)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Huntingtin (Huntington Disease Protein or HTT) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Huntingtin (Huntington Disease Protein or HTT) - Overview
- Huntingtin (Huntington Disease Protein or HTT) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Huntingtin (Huntington Disease Protein or HTT) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Huntingtin (Huntington Disease Protein or HTT) - Companies Involved in Therapeutics Development
- AFFiRiS AG
- Dystrogen Therapeutics SA
- Exicure Inc
- F. Hoffmann-La Roche Ltd
- Neurimmune Holding AG
- Ophidion Inc
- PTC Therapeutics Inc
- reMYND NV
- Takeda Pharmaceutical Co Ltd
- UniQure NV
- Voyager Therapeutics Inc
- Vybion Inc
- Wave Life Sciences Ltd
- Huntingtin (Huntington Disease Protein or HTT) - Drug Profiles
- AMT-130 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Antisense Oligonucleotides to Inhibit HTT for Huntington's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- DYST-201 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy to Inhibit HTT for Huntington's disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy to Inhibit Huntingtin for Huntington Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- INT-41 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibodies to Inhibit HTT for Huntington's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NI-302 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Oligonucleotide to Inhibit HTT for Huntington Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- P-301905 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RG-6042 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Synthetic Peptide to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Vaccine to Target Huntingtin for Huntington's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- VYHTT-01 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- WVE-120101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- WVE-120102 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Huntingtin (Huntington Disease Protein or HTT) - Dormant Products
- Huntingtin (Huntington Disease Protein or HTT) - Product Development Milestones
- Featured News & Press Releases
- Sep 27, 2019: uniQure to present update on of AMT-130 at European Huntington Association 2019 Conference
- Jul 01, 2019: Sangamo Therapeutics announces Nature Medicine publication detailing the activity of disease allele-selective zinc finger proteins in preclinical models of huntington's disease
- May 22, 2019: uniQure strengthens intellectual property portfolio with granted patent claims covering AMT-130 for huntington's disease
- May 07, 2019: uniQure announces featured presentations of new data on AMT-130 at the 2019 American Academy of Neurology Annual Meeting
- May 06, 2019: Huntington drug successfully lowers levels of disease-causing protein
- Apr 29, 2019: Genentech to present on its Huntington's Disease drug candidate RG-6042 at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
- Apr 15, 2019: uniQure to present data on Gene Therapy for Huntington's Disease at ASGCT 2019
- Apr 10, 2019: Wave Life Sciences provides timing update on PRECISION-HD clinical programs
- Apr 10, 2019: Wave Life Sciences provides timing update on WVE-120102 Clinical Program
- Apr 10, 2019: Wave Life Sciences provides timing update on WVE-120101 clinical Program
- Apr 08, 2019: uniQure receives FDA Fast Track Designation for AMT-130 gene therapy for the treatment of Huntington's Disease
- Apr 05, 2019: Dystrogen Therapeutics announces that gene therapy successfully cuts off production of neuron-destroying protein in Huntington's Disease
- Feb 27, 2019: uniQure presents new preclinical data on AMT-130 at the CHDI's 14th Annual Huntington's Disease Therapeutics Conference
- Jan 28, 2019: First patient enrolled in pivotal study of RG6042 (IONIS-HTT Rx) for people with Huntington's disease
- Jan 22, 2019: uniQure announces FDA clearance of investigational New Drug Application for AMT-130 in Huntington's Disease
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H2 2019
- Number of Products under Development by Therapy Areas, H2 2019
- Number of Products under Development by Indication, H2 2019
- Number of Products under Development by Companies, H2 2019
- Products under Development by Companies, H2 2019
- Products under Development by Companies, H2 2019 (Contd..1), H2 2019
- Number of Products under Investigation by Universities/Institutes, H2 2019
- Products under Investigation by Universities/Institutes, H2 2019
- Number of Products by Stage and Mechanism of Actions, H2 2019
- Number of Products by Stage and Route of Administration, H2 2019
- Number of Products by Stage and Molecule Type, H2 2019
- Pipeline by AFFiRiS AG, H2 2019
- Pipeline by Dystrogen Therapeutics SA, H2 2019
- Pipeline by Exicure Inc, H2 2019
- Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
- Pipeline by Neurimmune Holding AG, H2 2019
- Pipeline by Ophidion Inc, H2 2019
- Pipeline by PTC Therapeutics Inc, H2 2019
- Pipeline by reMYND NV, H2 2019
- Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
- Pipeline by UniQure NV, H2 2019
- Pipeline by Voyager Therapeutics Inc, H2 2019
- Pipeline by Vybion Inc, H2 2019
- Pipeline by Wave Life Sciences Ltd, H2 2019
- Dormant Projects, H2 2019
List of Figures
- Number of Products under Development by Stage of Development, H2 2019
- Number of Products under Development by Therapy Areas, H2 2019
- Number of Products under Development by Top 10 Indications, H2 2019
- Number of Products by Mechanism of Actions, H2 2019
- Number of Products by Stage and Mechanism of Actions, H2 2019
- Number of Products by Routes of Administration, H2 2019
- Number of Products by Stage and Routes of Administration, H2 2019
- Number of Products by Molecule Types, H2 2019
- Number of Products by Stage and Molecule Types, H2 2019
